Industry anger as off-label Avastin rears its head again
This article was originally published in SRA
Executive Summary
After the legislative upheavals in France and Italy, the Avastin v Lucentis saga has reared its head again in the UK, after clinical commissioning groups (CCGs) called on the government and NHS England to support doctors wanting to prescribe Roche's Avastin (bevacizumab) off label for wet age-related macular degeneration (AMD) in place of Novartis' more costly Lucentis (ranibizumab)1.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.